JP2002542256A - ピロリジンカルボニルアミノ環状ジスルフィド類 - Google Patents

ピロリジンカルボニルアミノ環状ジスルフィド類

Info

Publication number
JP2002542256A
JP2002542256A JP2000612324A JP2000612324A JP2002542256A JP 2002542256 A JP2002542256 A JP 2002542256A JP 2000612324 A JP2000612324 A JP 2000612324A JP 2000612324 A JP2000612324 A JP 2000612324A JP 2002542256 A JP2002542256 A JP 2002542256A
Authority
JP
Japan
Prior art keywords
compound
amino
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000612324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542256A5 (https=
Inventor
チェン，リー
フトゥヒ，ネーダー
ジャクソン，デービッド・ヤング
ティリー，ジェファソン・ライト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2002542256A publication Critical patent/JP2002542256A/ja
Publication of JP2002542256A5 publication Critical patent/JP2002542256A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000612324A 1999-04-20 2000-04-17 ピロリジンカルボニルアミノ環状ジスルフィド類 Pending JP2002542256A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US60/130,215 1999-04-20
PCT/EP2000/003459 WO2000063234A2 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists

Publications (2)

Publication Number Publication Date
JP2002542256A true JP2002542256A (ja) 2002-12-10
JP2002542256A5 JP2002542256A5 (https=) 2007-06-14

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000612324A Pending JP2002542256A (ja) 1999-04-20 2000-04-17 ピロリジンカルボニルアミノ環状ジスルフィド類

Country Status (15)

Country Link
US (1) US6265572B1 (https=)
EP (1) EP1171452B1 (https=)
JP (1) JP2002542256A (https=)
KR (1) KR100636481B1 (https=)
CN (1) CN1167710C (https=)
AR (1) AR023546A1 (https=)
AT (1) ATE337331T1 (https=)
AU (1) AU769294B2 (https=)
BR (1) BR0009838A (https=)
CA (1) CA2370259A1 (https=)
DE (1) DE60030266T2 (https=)
ES (1) ES2269141T3 (https=)
TR (1) TR200103004T2 (https=)
WO (1) WO2000063234A2 (https=)
ZA (1) ZA200108018B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
CA2598816A1 (en) * 2005-02-28 2006-08-31 Medichem S.A. Process and methods for the preparation of gabapentin and its intermediates
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2850885A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
BR0009838A (pt) 2002-01-08
EP1171452B1 (en) 2006-08-23
AR023546A1 (es) 2002-09-04
KR20010108517A (ko) 2001-12-07
AU4748200A (en) 2000-11-02
WO2000063234A3 (en) 2001-01-18
CA2370259A1 (en) 2000-10-26
US6265572B1 (en) 2001-07-24
EP1171452A2 (en) 2002-01-16
DE60030266T2 (de) 2007-07-19
TR200103004T2 (tr) 2002-01-21
AU769294B2 (en) 2004-01-22
ES2269141T3 (es) 2007-04-01
ATE337331T1 (de) 2006-09-15
DE60030266D1 (de) 2006-10-05
WO2000063234A2 (en) 2000-10-26
ZA200108018B (en) 2003-03-26
CN1347419A (zh) 2002-05-01
CN1167710C (zh) 2004-09-22
KR100636481B1 (ko) 2006-10-18

Similar Documents

Publication Publication Date Title
JP4340386B2 (ja) リンパ球機能抗原−１アンタゴニスト
US5529996A (en) 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
JP3181335B2 (ja) エンケファリナーゼ及びａｃｅの抑制剤として有用な、新規なメルカプトアセチルアミド誘導体類
RU2127260C1 (ru) Производные пергидроизоиндола, способы их получения и фармацевтическая композиция на их основе
AU2008287124B2 (en) Azepine derivatives as gamma-secretase inhibitors
RU2266901C2 (ru) 4-пиримидинил-n-ацил-l-фенилаланины и фармацевтическая композиция
JPH06340691A (ja) ペプチド類
SK1694A3 (en) Pyrolidine derivatives, preparation thereof and drugs containing same
JPH0267297A (ja) ジオール含有レニン阻害剤
KR20000075813A (ko) 항 염증성 화합물
EP0434365A2 (en) HIV protease inhibitors useful for the treatment of aids
JPH06503568A (ja) Ｈｉｖプロテアーゼ阻害剤
JP2002542256A (ja) ピロリジンカルボニルアミノ環状ジスルフィド類
JP4167806B2 (ja) メビノリン誘導体
JPH05222020A (ja) エイズの治療に有用なｈｉｖプロテアーゼインヒビター
US5491142A (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
JPS60136595A (ja) 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤
JPH08325152A (ja) Ａｃｅおよびｎｅｐの抑制に有用なベンゾ縮合アゼピノンおよびピペリジノン化合物
JPH06508146A (ja) 炭素環および複素環式ｈｉｖプロテアーゼ抑制剤
US5604221A (en) Indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
HU193909B (en) Process for preparing novel 1-4-dihydropyridine-carboxamide derivatives and pharmaceutics comprising these compounds
MXPA01010543A (en) Pyrrolidincarbonylamino cyclic disulfides
JPH07173142A (ja) ３（ｓ）−アミノ−４−シクロヘキシル−２（ｒ）−ヒドロキシ−酪酸又は４−シクロヘキシル−（２ｒ，３ｓ）−ジヒドロキシ−酪酸又は関連同族体を含む環状レニン阻害剤
JPH0461878B2 (https=)
JPH11503450A (ja) Ｃ−末端アミネルジックな側鎖アミノ酸残基を含む血小板凝集抑制物質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100727